Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-) NETs: Post Hoc Analyses from the CLARINET Study

#1193

Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.

Aim(s): To report exploratory post hoc analyses of treatment impact on specific aspects of HRQoL, and explore possible prognostic factors for changes in these HRQoL aspects.

Materials and methods: Patients (n=204) completed EORTC QLQ-C30 and QLQ-GI.NET21 every 12 wks. Analyses reported are: GI.NET21 endocrine (ENDO) and GI symptoms scales; QLQ-C30 physical functioning (PF) scale. Treatment effects assessed using logistic regression to determine relative odds of unchanged/improved vs deteriorated HRQoL at last value within subgroups defined by baseline (BL) characteristics. Prognostic factors (BL characteristics) assessed for unchanged/improved vs deteriorated HRQoL using exploratory logistic regression model (p<0.1 for inclusion/exclusion).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: lanreotide, quality of life,